GlassScriptPhysician profile
Heather Glenn
NPI 1952460636
$4,336.25
in general payments reported to CMS, 2019-2025
40 companies · $1,661 in 2025
The $1,661 reported for 2025 was more than what 92% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $852 · 2023: $686 · 2024: $1,137 · 2025: $1,661.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,247 · Education: $237.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,247.24 |
| Education | $236.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $670.05 | 2022-2025 | Darzalex, Tecvayli, Rybrevant |
| Rigel Pharmaceuticals, INC. | $537.80 | 2023-2025 | Rezlidhia, Tavalisse, Tavalisse |
| Abbvie INC. | $312.27 | 2024-2025 | |
| Pfizer INC. | $247.61 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $229.50 | 2022-2025 | Keytruda, Welireg, Lynparza |
| Astellas Pharma US INC | $221.52 | 2023-2025 | Vyloy, Padcev, Xospata |
| Jazz Pharmaceuticals INC. | $177.63 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $169.79 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $168.11 | 2022-2025 | |
| Celgene Corporation | $160.77 | 2022-2025 | Reblozyl, Pomalyst |
| Adc Therapeutics America, INC. | $138.29 | 2024-2025 | |
| Incyte Corporation | $105.83 | 2022-2025 | Jakafi, Monjuvi, Pemazyre |
| Eisai INC. | $97.18 | 2023-2025 | |
| Karyopharm Therapeutics INC. | $87.74 | 2022-2025 | Xpovio |
| Gilead Sciences, INC. | $81.64 | 2023-2025 | Trodelvy |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sobi, INC | $74.11 | 2022-2025 | |
| Amgen INC. | $64.26 | 2022-2023 | Lumakras |
| Mirati Therapeutics, INC. | $62.00 | 2023-2024 | Krazati |
| Takeda Pharmaceuticals U.S.A., INC. | $57.53 | 2024-2025 | Fruzaqla |
| Springworks Therapeutics, INC. | $50.87 | 2024-2025 | Ogsiveo |
| Exelixis INC. | $49.04 | 2025 | Cabometyx |
| Daiichi Sankyo INC. | $48.65 | 2025 | Enhertu, Datroway |
| Ipsen Biopharmaceuticals, INC | $45.13 | 2022 | |
| Array Biopharma INC | $43.94 | 2025 | Braftovi, Tukysa, Mektovi |
| Novo Nordisk INC | $41.37 | 2022-2025 | |
| Blueprint Medicines Corporation | $40.87 | 2022 | |
| Morphosys, US INC. | $36.73 | 2022 | |
| Caris Mpi, INC. | $35.01 | 2025 | Mi Cancer Seek |
| Seagen INC. | $31.75 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $28.92 | 2025 | Libtayo |
| Puma Biotechnology, INC. | $28.51 | 2025 | |
| Dendreon Pharmaceuticals LLC | $28.35 | 2025 | Provenge |
| Lilly USA, LLC | $28.26 | 2022 | |
| Genzyme Corporation | $26.21 | 2025 | |
| Taiho Oncology, INC. | $21.90 | 2024 | |
| Janssen Pharmaceuticals, INC | $21.07 | 2024 | Xarelto |
| Glaxosmithkline, LLC. | $18.32 | 2023 | Jemperli, Zejula |
| Xeris Pharmaceuticals, INC. | $17.31 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $15.43 | 2023 | Epanova |
| Agios Pharmaceuticals, INC. | $14.98 | 2025 | Pyrukynd |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Heather Glenn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.